吉西他滨联合顺铂治疗非小细胞肺癌患者的应用价值

The Application Value of Gemcitabine plus Cisplatin in the Treatment of Non-small Cell Lung Cancer

目的探讨吉西他滨联合顺铂在临床上治疗非小细胞肺癌中的应用价值。方法选取2009年5月至2011年4月来我院就诊治疗的80例非小细胞肺癌患者,将其分为治疗组和对照组两组,每组40例。其中对照组患者采用单纯吉西他滨治疗,治疗组患者则采用吉西他滨联合顺铂治疗,8周后计算患者的疾病控制率(RR),并对两组患者进行效价比较。结果 2个月后,对照组患者的疾病控制率(RR)为52.5%,治疗组患者的疾病控制率(RR)为85.0%,P<0.05。结论吉西他滨在治疗非小细胞肺癌上有着较好的效果,当其与顺铂联合使用时,在临床上对非小细胞肺癌患者的效果更佳,而且不良反应可被有效控制,所以我们认为吉西他滨联合顺铂治疗非小细胞肺癌是一种值得推广的临床治疗方案。

To investigate the value of gemcitabine plus cisplatin in the clinical treatment of nonsmall cell lung cancer application. Methods From May 2009 to April 2011, 80 patients with nonsmall cell lung cancer patients were chosen who were treated in our hospital. Divided them into two groups（treatment group and control group）. There were 40 cases in each group. Patients of control group were treated with gemcitabine alone, patients of treatment group were treated with gemcitabine plus cisplatin. The disease control rate （RR） was calculated after 8 weeks＇treatment and compared them. Resnlts 2 months later, the control group of patients with disease control rate （RR） was 52.5% and patients treated with disease control rate （RR） was 85.0%, P〈0.05. Conclusion Gemcitabine in the treatment of nonsmall cell lung cancer has a good effect, and its combination with cisplatin when used in clinical nonsmall cell lung cancer patients is better and adverse reactions can be effectively controlled. So we think that gemcitabine plus cisplatin in the treatment of nonsmall cell lung cancer is a worthy clinical treatment.